Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MSD India's out-of-the-box Hep C financing: how, why & what next?

This article was originally published in Scrip

Executive Summary

When Biotechnology Industry Organization (BIO) president and CEO Jim Greenwood suggested that consumers paying for their expensive cancer or hepatitis C virus (HCV) treatments through direct financing deals with manufacturers may be a possible solution to dealing with the high prices of some prescription medications (scripintelligence.com 9 June 2014), he probably didn't realize that smart Merck & Co executives in India were already experimenting with a pilot along those lines.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC025515

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel